NCT04756037 2026-01-08SERENESumitomo Pharma Switzerland GmbHPhase 3 Active not recruiting1,020 enrolled
NCT05862272 2025-08-06A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisSumitomo Pharma Switzerland GmbHPhase 3 Recruiting1,000 enrolled